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Cure rates have been improving in the treatment of ALL, mainly in pediatrics. Nevertheless, nobody can read what is on the cards, nor can they ever predict whether a single child with ALL would be ultimately cured or not. Biological prognostic features and multi-step assessment of response to therapy can help to better stratify patients and tailor treatment.
Minimal residual disease (MRD) is one of the most powerful tools available to predict the risk of relapse. 1 As expected, though, even allocation by MRD results cannot account for all relapse events, as further intensified chemotherapy treatment might change the course of the disease after each measurement. When no further chemotherapy is planned, as after transplantation, MRD detection would be expected to be invariably associated with relapse. This is not the case, fortunately, as we learnt in the last decade, consistently for different groups.
2-6 MRD positivity after transplant was associated with a 40% probability of survival in our series of 82 transplanted pediatric patients, as previously reported. 2 This unexpected, relatively favorable outcome in patients who develop any MRD positivity after transplantation is actually considered as an additional proof of the existence of the GvL effect, which is regarded as the main factor that can prevent relapse in the presence of leukemic cells. 7 Furthermore, immunomodulatory strategies, such as early tapering/discontinuation of immunosuppression and donor lymphocyte infusion (DLI) or other cell therapies, have been applied in order to enhance GvL. 2, [6] [7] [8] [9] It is well demonstrated that ALL patients experiencing any MRD positivity after transplant have a worse outcome compared with patients for whom no MRD could be detected in the post-transplant course. Nevertheless, whether the dismal the dismal prognostic impact of MRD positivity after transplant could be reset or at least improved by the alloreactivity elicited by any immunological intervention is still to be assessed, 10, 11 even though there are clues that it is the case. 8 An alternative explanation for long-term continuous CR (CCR) in the presence of MRD-positive results after transplant would be indeed that those positive results were actually false-positive results. 12 This is cumbersome, as laboratory results are often regarded as absolute truths. Nevertheless, we all know that any laboratory output is subject to a certain degree of false-positiveness and false-negativeness, which account for the sensitivity and the specificity of each test.
Two different hypotheses could yield false-positive results in epidemiology. First, despite the positive result of a screening test being well taken, the disease does not occur, which is possible, since the predictive value of any test is not 100%. Second, the result is wrong; therefore the disease does not occur, and the non-predictability is due to a mistaken screening test.
MRD measurement could well be considered as a screening test potentially predictive of disease relapse. According to the former hypothesis, leukemic cells would be present, but they would not ultimately proliferate, possibly due to the GvL effect. According to the latter hypothesis, the disease rearrangement would be amplified not specifically in the absence of leukemic cells.
The detection of an amplification signal below the quantitative range is defined in the laboratory report as a result that is MRD positive but 'non-quantifiable'.
13 When I receive a doubtful result, as a clinician, I am used to talking with my colleagues in the laboratory, in an attempt to gain additional information that could better direct my medical interventions. In the event of non-quantifiable MRD, some information cannot be added on the interpretation of the assay. According to the EuroMRD Guidelines, which standardize molecular MRD measurements in our laboratories, a positive signal could not be quantified if (1) it is detected outside of the quantitative range, (2) it is not reproducible (o 1.5 cycle threshold (C T ) among the three replicates) and (3) it is assessed in only one or two of the three replicates or it is at less than one (or three) PCR 'cycles' compared to the healthy controls/ background.
13,14
The above information provided me with further insights that changed my perspective as a clinician. Non-quantifiable MRD results came from assays that could not quantify the amount of disease, but also from assays in which the disease may not even have been there! The label 'non-quantifiable' positivity was created for clinical purposes and refers to quantitative PCR (qPCR) results. The definition 'non-quantifiable MRD' was misleading to me and now I operationally substitute it with the label 'uncertain MRD positivity'.
Somebody in the laboratory took the time to make me realize that such a sensitive technique could reveal nonspecific amplification of comparable Ig/TCR gene rearrangements in normal cells from healthy controls, as previously reported. Nonspecific amplification is generally detected only at low levels and outside the quantitative range of the qPCR, with the lowest C T value of these nonspecific amplification controls specified as the (highest) background level.
In a setting where MRD-driven therapy reduction might apply, EuroMRD Guidelines recommend more conservative criteria, in order to limit false-negative results. A sample is considered to be MRD positive if the C T value of at least one of the three replicates is × 1.0 C T lower than the lowest C T of the background and the C T value of at least one of the three replicates is within 4.0C T from the highest C T value of the 'sensitivity'.
On the contrary, when MRD-driven therapy intensification might apply, EuroMRD Guidelines recommend more stringent criteria in order to limit false-positive results. A sample is considered to be MRD positive only if it gives amplification at a level clearly apart from the background. A sample is considered to be MRD positive if the C T value of at least one of the three replicates is × 3.0 C T lower than the lowest C T of the background and the C T value of at least one of the three replicates is within 4.0C T from the highest C T value of the sensitivity level. 13, 14 In the post-transplant course no modification could be undertaken, but only therapy intensification, such as immunomodulation or DLI; therefore the latter criteria would apply, as in the Kotrova's study in this issue of BMT. 15 Nevertheless, earliest recognition of even lowest positivity levels after transplant, although not 'reproducible or accurate', is considered crucial in order to optimize the timing of any intervention; thus, many groups, like ours, have so far adopted the former criteria and accepted a higher rate of false positivities.
I started considering the hypothesis that patients with posttransplant non-quantifiable MRD, whom I had assumed I had rescued with my immunological interventions, might have never been positive nor needed my interventions.
2 I was in the process of updating and reassessing my MRD data when I came across an interesting paper to comment, in this issue of BMT.
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The Childhood Leukemia Investigation Prague (CLIP), Laboratory Centre, Department of Pediatric Hematology/Oncology of the second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic, is well acknowledged in the MRD field, being a founding member of the EuroMRD Group. They have published pivotal studies on the issue of false-positive MRD results in the last decade. [12] [13] [14] [15] [16] In a previous report in BMT in 2008, the same group retrospectively analyzed MRD-positive results observed in 21 transplanted patients who had subsequently experienced no disease recurrence. 12 Those positivities were interpreted as the result of nonspecific amplification in physiologic lymphocytes, as shown by the facts that (1) similar results were obtained with two non-self-specific Ig heavy-chain assays, (2) nonspecific amplified products differed from the specific products in length and sequence, (3) the phenomenon correlated with flow-cytometryproven B-cell regeneration in the bone marrow and Ig light chain-kappa excision circle quantification and (4) fusion transcript detection, in patients carrying fusion genes, was constantly negative. 12 Moreover, the 'CLIP' team measured the length of PCR products by means of an Agilent device in order to reveal false-positive results and avoid overtreatment in the post-transplantation setting. 12 More recently, the same group compared MRD measurements by qPCR and next-generation sequencing (NGS) and their prognostic significance on days +15, +33 and +78 after the initiation of chemotherapy for ALL and found that discrepancies, mostly in low-positive samples, allowed NGS to provide an even more precise prediction of relapse than qPCR, mainly at day 33. 16 In this issue of BMT, Kotrova et al. 15 readdressed the issue of false MRD positivity in the post-transplant course. Some non-quantifiable positive MRD results obtained with qPCR were re-analyzed by means of NGS in a series of 30 pediatric ALL patients transplanted in Prague and Rotterdam between 2000 and 2014. NGS is proposed as an additional more specific technique, in particular to assess non-quantifiable positive samples assessed by qPCR and potentially discriminate false-from true-positive results. 15 The eligibility criterion for the study was the presence of at least one MRD non-quantifiable positive result detected by qPCR, as strictly defined by 'EuroMRD' guidelines. Patients were divided a posteriori into two groups based on the occurrence of post-transplant relapse; the additional criteria were an event-free survival time after transplantation of at least 2 years for the 17 CCR cases and the occurrence of relapse any time for the 13 'relapsed' controls. 15 The authors state that NGS was far more accurate for relapse prediction than qPCR, and that a substantial proportion of positive not quantifiable post-transplantation results were most likely false positives. 15 Forty of fifty-eight non-quantifiable MRD-positive samples by qPCR (plus two positive) have been analyzed by NGS, out of a total of 228 samples; 31 were detected as negative and 9 positive by NGS. Twenty-seven of the thirty-four non-quantifiable positive samples in the CCR patients have been re-analyzed and only one of them was found positive by NGS. Thirteen of the twenty-four non-quantifiable positive samples in the relapsed patients have also been analyzed by NGS and ten of them were found positive. The difference in the ratio (1 of 27 versus 10 of 13) between the proportion of the positive patients by NGS, out of the total non-quantifiable positive cases identified by qPCR in the CCR and in the relapsed cohort, is striking and highly significant. Even though the pattern of results for some relapsed patients did not differ from the pattern of those who remained long term in CR, the predictive value of NGS versus qPCR was much higher, as stated by the authors. 15 Only qPCR primers with at least 1E − 04 sensitivity were considered, despite the quantitative range being not specified. In particular, it would be interesting to know the quantitative range for the positive samples identified by qPCR that were negative by NGS, in order to comment on marker quality and then accuracy of qPCR results. Moreover, it is likely that the same amount of DNA was correctly used, in order to compare the two techniques.
In terms of targets, 26 false qPCR positivities involved VH genes and most detections were beyond 100 days after transplantation, while B-cell regeneration, mainly of mature cells, is the highest. TCR gamma was positive in three out of four peripheral blood samples, where T-cell regeneration is the highest.
The two figures of the paper clearly show the pattern of MRD by time and investigate the role of NGS in predicting relapse. Noticeably, NGS added a contribution in predicting relapse compared with qPCR results in eight patients; nevertheless, in six of them NGS-positive results were assessed in the sample just before relapse. Therefore, it is to be assessed whether an earlier monitoring could have anticipated the diagnosis of impending relapse.
None of the 160 negative samples identified by qPCR has been analyzed by NGS, so no comments can be made about the presence of false-negative results by qPCR or the predictive value of NGS-negative results.
All patients who experienced a quantifiable positive MRD by qPCR did eventually relapse, but for a single patient who was positive in the first month only. It could be stated that not only all quantifiable results were true positivities, but also that none of them could be rescued. On the other hand, seven patients of the relapsing cohort had non-quantifiable MRD positivity only and five of them would have been discovered by NGS. Furthermore, six patients had developed quantifiable MRD subsequently to non-quantifiable results; nevertheless, waiting for MRD levels to become quantifiable could jeopardize the efficacy of any intervention.
The article is very interesting and deals with three crucial issues. First, it highlights that non-quantifiable MRD results might be false positivities. As the authors state, the antigen receptor-based qPCR method 'has some technical and biological pitfalls that need to be considered when interpreting data'. Length measurement of qPCR products could reveal non-clonality and rule out MRD positivity in up to 30-40% of the so-called non-quantifiable positive results. 12 However, more than half of the non-quantifiable positivities could be neither confirmed nor ruled out.
Second, it proposes NGS as a method to discriminate false positivities. All those who became quantifiable qPCR MRD positive ultimately relapsed in this series. Many of those in whom a non-quantifiable MRD was detected did not relapse. Whether they were 'false positive' or, despite being 'true positive', have been rescued could not be further assessed by qPCR. The additional impact of NGS compared with 'quantifiable qPCR positivity assessment' could have predicted eight additional relapses, but with a very short notice prior to overt relapse for most of them. The NGS analyses of a few samples, with a median of one sample only for each patient, does not allow to state in the present study how much in advance the prediction could be made by NGS, which makes it difficult to estimate the existence of a window for any potentially effective intervention.
Third, it suggests that NGS might replace qPCR in MRD monitoring, particularly after transplantation. Only a prospective validation study comparing the two methods could assess whether NGS would be superior to qPCR. The comparison between the two techniques should take into account many variables, including marker quality, DNA amount, timing after transplant and so on.
Strict guidelines should be elaborated also in order to standardize NGS, as well as it was done for qPCR. It wouldn't be surprising if the CLIP team played a pivotal role in such a process. When costs are taken into account, NGS techniques would become efficient tools only when many samples are gathered.
Will NGS replace qPCR? Veritatem dies aperit. Time will tell…
